Management of the dialysis patient in general intensive care

British Journal of Anaesthesia

Volumn 108, Issue 2, 2012, Pages 183-192

  Arulkumaran, N ^a   Montero, R M ^a   Singer, M ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cardiovascular; electrolyte; end stage renal disease; pharmacology; sepsis

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CALCITONIN; CALCIUM ION; CINACALCET; CITRIC ACID; CREATINE KINASE MB; FENTANYL; FUROSEMIDE; GLUCONATE CALCIUM; HEPARIN; HYDROMORPHONE; INSULIN; MAGNESIUM ION; MIDAZOLAM; MORPHINE; MORPHINE DERIVATIVE; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM; PROPOFOL; REMIFENTANIL; SALBUTAMOL; SUXAMETHONIUM; TROPONIN I; TROPONIN T; UNINDEXED DRUG;

ACID BASE BALANCE; ANALGESIA; ANTICOAGULATION; ARTERIOVENOUS FISTULA; BACTEREMIA; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CENTRAL VENOUS PRESSURE; COMORBIDITY; CONTINUOUS HEMOFILTRATION; DEFIBRILLATOR; DIALYSIS CATHETER; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG USE; DRY WEIGHT; ELECTROLYTE DISTURBANCE; GLOMERULUS FILTRATION RATE; GLUCURONIDATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART MUSCLE INJURY; HEART OUTPUT MEASUREMENT; HEMODIALYSIS PATIENT; HOSPITAL ADMISSION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPOCALCEMIA; INFECTION RISK; INTENSIVE CARE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LUNG EDEMA; MAGNESIUM BLOOD LEVEL; MAGNESIUM EXCRETION; METABOLIC CLEARANCE RATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PATIENT MONITORING; PERITONEAL DIALYSIS; PERITONITIS; PHARMACODYNAMICS; PHARMACOKINETICS; PHLEBOTOMY; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRESCRIPTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESIDUAL URINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SEPSIS; SUDDEN DEATH; SUPERIOR CAVA VEIN OBSTRUCTION; THROMBOSIS; URINARY EXCRETION; VASCULAR ACCESS;

EID: 84856261009     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aer461     Document Type: Review

References (109)

1. US Renal Data System. USRDS 2009 Annual Data Report. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009
2. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 997-9 (Pubitemid 43357803)
3. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-8 (Pubitemid 47531190)
4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney diseaseinthe United States.J AmMed Assoc 2007; 298: 2038-47 (Pubitemid 350074801)
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospi-talization. N Engl J Med 2004; 351: 1296-305
6. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68: 818-25 (Pubitemid 43323139)
7. Hutchison CA, Crowe AV, Stevens PE, Harrison DA, Lipkin GW. Case mix, outcome and activity for patients admitted to intensive care units requiring chronic renal dialysis: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care 2007; 11: R50
8. Uchino S, Morimatsu H, Bellomo R, Silvester W, Cole L. End-stage renal failure patients requiring renal replacement therapy in the intensive care unit: incidence, clinical features, and outcome. Blood Purif 2003; 21: 170-5 (Pubitemid 36302368)
9. NKF-National Kidney Foundation U. NKF KDOQUI Guidelines 2000. 2000. Available from http://www.kidney.org/professionals/kdoqi/guidelines-updates/ doqiuppd-viii.html
10. Canaud B, Desmeules S, Klouche K, Leray-Moragues H, Beraud JJ. Vascular access for dialysis in the intensive care unit. Best Pract Res Clin Anaesthesiol 2004; 18: 159-74 (Pubitemid 38949990)
11. Zoccali C, Mallamaci F, Tripepi G. Hypertension as a cardiovascular risk factor in end-stage renal failure. Curr Hypertens Rep 2002; 4: 381-6
12. Leypoldt JK, Cheung AK, Delmez JA, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int 2002; 61: 266-75 (Pubitemid 34075154)
13. Charra B, Chazot C. Volume control, blood pressure and cardiovascular function. Lessons from hemodialysis treatment. Nephron Physiol 2003; 93: 94-101
14. Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59: 754-63 (Pubitemid 32157942)
15. Halle MP, Hertig A, Kengne AP, Ashuntantang G, Rondeau E, Ridel C. Acute pulmonary oedema in chronic dialysis patients admitted into an intensive care unit. Nephrol Dial Transplant Advance Access published on May 26, 2011, doi:10.1093/ndt/gfr290
16. Evans K, Reddan DN, Szczech LA. Nondialytic management of hyperkalemia and pulmonary edema among end-stage renal disease patients: an evaluation of the evidence. Semin Dial 2004; 17: 22-9 (Pubitemid 38376688)
17. Eiser AR, Lieber JJ, Neff MS. Phlebotomy for pulmonary edema in dialysis patients. Clin Nephrol 1997; 47: 47-9 (Pubitemid 27052804)
18. Kanbay M, Afsar B, Goldsmith D, Covic A. Sudden death in hemo-dialysis: an update. Blood Purif 2010; 30: 135-45
19. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56: 210-6
20. Bozbas H, Atar I, Yildirir A, et al. Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis. Ren Fail 2007; 29: 331-9 (Pubitemid 46752353)
21. Malhis M, Al-Bitar S, Farhood S, Zaiat KA. Changes in QT intervals in patients with end-stage renal disease before and after hemo-dialysis. Saudi J Kidney Dis Transpl 2010; 21: 460-5
22. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011; 79: 218-27
23. Charytan DM, Patrick AR, LiuJ,et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011; 58: 409-17
24. Fehr T, Knoflach A, Ammann P, Pei P, Binswanger U. Differential use of cardiac troponin T versus I in hemodialysis patients. Clin Nephrol 2003; 59: 35-9 (Pubitemid 36150463)
25. Donnino MW, Karriem-Norwood V, Rivers EP, et al. Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis. Acad Emerg Med 2004; 11: 979-81 (Pubitemid 39149933)
26. Korkmaz H, Sasak G, Celik A, et al. The comparison of cardiac biomarkers positivities in hemodialysis patients without acute coronary syndrome. Ren Fail 2011; 33: 578-81
27. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37: 350-6 (Pubitemid 46653136)
28. Sommerer C, Heckele S, Schwenger V, Katus HA, Giannitsis E, Zeier M. Cardiac biomarkers are influenced by dialysis characteristics. Clin Nephrol 2007; 68: 392-400 (Pubitemid 350258768)
29. Sommerer C, Giannitsis E, Schwenger V, Zeier M. Cardiac biomar-kers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T. Nephron Clin Pract 2007; 107: c77-81 (Pubitemid 350073611)
30. Breidthardt T, Kalbermatter S, Socrates T, et al. Increasing B-type natriuretic peptide levels predict mortality in unselected haemo-dialysis patients. Eur J Heart Fail 2011; 13: 860-7
31. Kang EW, Na HJ, Hong SM, et al. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis. Nephrol Dial Transplant 2009; 24: 1568-73
32. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758-64
33. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5
34. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992; 42: 663-7
35. Sunder-Plassmann G, Sedlacek PL, Sunder-Plassmann R, et al. Anti-interleukin-1 alpha autoantibodies in hemodialysis patients. Kidney Int 1991; 40: 787-91
36. Vanholder R, Van Loo A, Dhondt AM, De Smet R, Ringoir S. Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant 1996; 11: 593-8 (Pubitemid 26114538)
37. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77
38. Donnino M, Shirazi E, Wira C, et al. Early goal-directed therapy in patients with end-stage renal disease. 24th International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium. Crit Care 2004; 8 (suppl. 1): 163
39. Bibb JL, Servilla KS, Gibel LJ, et al. Pyocystis in patients on chronic dialysis. A potentially misdiagnosed syndrome. Int Urol Nephrol 2002; 34: 415-8 (Pubitemid 36896231)
40. Aslam N, Bernardini J, Fried L, Burr R, Piraino B. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol 2006; 1: 1226-33
41. Johnson DW, Dent H, Hawley CM, et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis 2009; 53: 290-7
42. Saad TF. Bacteremia associated with tunneled, cuffed hemodi-alysis catheters. Am J Kidney Dis 1999; 34: 1114-24
43. Nassar GM, Ayus JC. Infectious complications of the hemodialy-sis access. Kidney Int 2001; 60: 1-13
44. Duncan ND, Singh S, Cairns TD, et al. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant 2004; 19: 2816-22 (Pubitemid 39480978)
45. Fluck R, Wilson J, Davies J, Blackburn R, O'Donoghue D, Tomson CR. UK Renal Registry 11th Annual Report (December 2008): Chapter 12: epidemiology of methicillin resistant Staphylococcus aureus bacteraemia amongst patients receiving renal replacement therapy in England in 2007. Nephron Clin Pract 2010; 115 (suppl. 1): c261-70
46. Chu FY, Hsu SP, Chen HY, et al. Nasal carriage of methicillin-resistant Staphylococcus aureus is associated with higher all-cause mortality in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 167-74
47. Fluck R, Wilson J, Tomson CR. UK Renal Registry 12th Annual Report (December 2009): Chapter 12: epidemiology of methicil-lin resistant Staphylococcus aureus bacteraemia amongst patients receiving dialysis for established renal failure in England in 2008: a joint report from the UK Renal Registry and the Health Protection Agency. Nephron Clin Pract 2010; 115(Suppl. 1): c261-70
48. Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 2006; 103: S55-62 (Pubitemid 44684776)
49. Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30: 393-423
50. Wiggins KJ, Craig JC, Johnson DW, Strippoli GF. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev 2008; CD005284
51. Khan A, Rigatto C, Verrelli M, et al. High Rates of Mortality and Technique Failure in Peritoneal Dialysis Patients after Critical Illness. Perit Dial Int Advance Access published on June 30, 2011
52. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009; 29: 297-302
53. Govindarajulu S, Hawley CM, McDonald SP, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. Perit Dial Int 2011; 30: 311-9
54. Halperin ML, Kamel KS. Potassium. Lancet 1998; 352: 135-40 (Pubitemid 28322749)
55. Sandle GI, Gaiger E, Tapster S, Goodship TH. Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) 1987; 73: 247-52 (Pubitemid 17095101)
56. Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol 2011; 7: 75-84
57. Liou HH, Chiang SS, Wu SC, et al. Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure: comparative study. Am J Kidney Dis 1994; 23: 266-71
58. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005; CD003235
59. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990; 38: 869-72 (Pubitemid 20362856)
60. Yentis SM. Suxamethonium and hyperkalaemia. Anaesth Intensive Care 1990; 18: 92-101 (Pubitemid 20241013)
61. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104: 158-69
62. Miller PD, Waterhouse C, Owens R, Cohen E. The effect of potassium loading on sodium excretion and plasma renin activity in Addisonian man. J Clin Invest 1975; 56: 346-53
63. Musso CG. Potassium metabolism in patients with chronic kidney disease. Part II: patients on dialysis (stage 5). Int Urol Nephrol 2004; 36: 469-72
64. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010; 362: 56-65
65. Cooper MS, Gittoes NJ. Diagnosis and management of hypocal-caemia. Br Med J 2008; 336: 1298-302
66. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003; 24: 47-66
67. Brain M, Parkes S, Fowler P, Robertson I, Brown A. Calcium flux in continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc 2010; 13: 72-81
68. Sekine M, Takami H. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Oncol Rep 1998; 5: 197-9 (Pubitemid 28039846)
69. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032-45
70. Frazao JM, Messa P, Mellotte GJ, et al. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin Nephrol 2011; 76: 233-43
71. Sramek V, Novak I, Matejovic M, et al. Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. Intensive Care Med 1998; 24: 262-4 (Pubitemid 28190821)
72. Crook M. A study of hypermagnesaemia in a hospital population. Clin Chem Lab Med 1999; 37: 449-51 (Pubitemid 29218966)
73. Favetta P, Degoute CS, Perdrix JP, Dufresne C, Boulieu R, Guitton J. Propofol metabolites in man following propofol induction and maintenance. Br J Anaesth 2002; 88: 653-8 (Pubitemid 34498593)
74. Hiraoka H, Yamamoto K, Miyoshi S, et al. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol 2005; 60: 176-82 (Pubitemid 41075903)
75. Takizawa D, Hiraoka H, Goto F, Yamamoto K, Horiuchi R. Human kidneys play an important role in the elimination of propofol. Anesthesiology 2005; 102: 327-30 (Pubitemid 40189080)
76. Eddleston JM, Pollard BJ, Blades JF, Doran B. The use of propofol for sedation of critically ill patients undergoing haemodiafiltra-tion. Intensive Care Med 1995; 21: 342-7
77. Spina SP, Ensom MH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 2007; 27: 389-98 (Pubitemid 46327906)
78. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-28
79. Boulieu R, Lehmann B, Salord F, Fisher C, Morlet D. Pharmacokin-etics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. Eur J Drug Metab Pharmacokinet 1998; 23: 255-8 (Pubitemid 28401116)
80. Driessen JJ, Vree TB, Guelen PJ. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 1991; 42: 149-55
81. Calvo R, Suarez E, Rodriguez-Sasiain JM, Martinez I. The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study. Res Commun Chem Pathol Pharmacol 1992; 78: 311-20 (Pubitemid 23009185)
82. Swart EL, de Jongh J, Zuideveld KP, Danhof M, Thijs LG, Strack van Schijndel RJ. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis 2005; 45: 360-71 (Pubitemid 40431063)
83. Dahan A, van Dorp E, Smith T, Yassen A. Morphine-6-glucuronide (M6G) for postoperative pain relief. Eur J Pain 2008; 12: 403-11 (Pubitemid 351312894)
84. Smith MT. Neuroexcitatory effects of morphine and hydromor-phone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27: 524-8 (Pubitemid 30417999)
85. Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmaco-kinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993; 54: 158-67 (Pubitemid 23265046)
86. Guay DR, Awni WM, Findlay JW, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43: 63-71 (Pubitemid 18052023)
87. Jamal JA, Joh J, Bastani B. Removal of morphine with the new high-efficiency and high-flux membranes during haemofiltra-tion and haemodiafiltration. Nephrol Dial Transplant 1998; 13: 1535-7 (Pubitemid 28254333)
88. Bastani B, Jamal JA. Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 1997; 12: 2802-4 (Pubitemid 27520736)
89. Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3- glucuronide in hemodi-alysis patients. J Opioid Manag 2008; 4: 335-6, 339-44
90. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28: 497-504 (Pubitemid 39422488)
91. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17: 746-52 (Pubitemid 27318968)
92. Chauvin M, Lebrault C, Levron JC, Duvaldestin P. Pharmacokinet-ics of alfentanil in chronic renal failure. Anesth Analg 1987; 66: 53-6 (Pubitemid 17101692)
93. Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology 1997; 87: 533-41 (Pubitemid 27433001)
94. Breen D, Wilmer A, Bodenham A, et al. Offset of pharmacody-namic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care 2004; 8: R21-30
95. Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002; 13: 798-805 (Pubitemid 34183949)
96. Suki WN. Use of diuretics in chronic renal failure. Kidney Int Suppl 1997; 59: S33-5 (Pubitemid 27252817)
97. Swan SK. Diuretic strategies in patients with renal failure. Drugs 1994; 48: 380-5 (Pubitemid 24264275)
98. Andreucci M, Russo D, Fuiano G, Minutolo R, Andreucci VE. Diuretics in renal failure. Miner Electrolyte Metab 1999; 25: 32-8 (Pubitemid 29196630)
99. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoi-etin. J Ren Nutr 2005; 15: 137-41 (Pubitemid 40093698)
100. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin- receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. Can Med Assoc J 2007; 177: 725-34 (Pubitemid 47523553)
101. Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003; 18: 1834-41 (Pubitemid 37098556)
102. Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009; 22: 279-86
103. Bramham K, Varrier M, Asgari E, Makanjuola D. Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity. Nephron Clin Pract 2008; 110: c107-13
104. Sonawane S, Kasbekar N, Berns JS. The safety of heparins in end-stage renal disease. Semin Dial 2006; 19: 305-10 (Pubitemid 44091705)
105. Clark JA, Schulman G, Golper TA. Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clin J Am Soc Nephrol 2008; 3: 736-42
106. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-7 (Pubitemid 41623398)
107. Morgera S, Scholle C, Melzer C, et al. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004; 98: c35-40 (Pubitemid 39279377)
108. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29: 562-77
109. Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011; 39: 560-70